These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

924 related items for PubMed ID: 19305378

  • 21. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C, Einstein M, Lucey MR, Said A.
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R, Lebrec D.
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [Abstract] [Full Text] [Related]

  • 24. Hepatorenal syndrome: a critical update.
    Wadei HM.
    Semin Respir Crit Care Med; 2012 Feb; 33(1):55-69. PubMed ID: 22447261
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy.
    Arroyo V.
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():49-54; discussion 55-6. PubMed ID: 15335402
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. New insights into the management of hepato-renal syndrome.
    Hasper D, Jörres A.
    Liver Int; 2011 Sep; 31 Suppl 3():27-30. PubMed ID: 21824281
    [Abstract] [Full Text] [Related]

  • 30. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.
    Meltzer J, Brentjens TE.
    Curr Opin Anaesthesiol; 2010 Apr; 23(2):139-44. PubMed ID: 20124895
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.
    Angeli P, Merkel C.
    J Hepatol; 2008 Apr; 48 Suppl 1():S93-103. PubMed ID: 18304678
    [Abstract] [Full Text] [Related]

  • 35. Hepatorenal syndrome: a dreaded complication of end-stage liver disease.
    Cárdenas A.
    Am J Gastroenterol; 2005 Feb; 100(2):460-7. PubMed ID: 15667508
    [Abstract] [Full Text] [Related]

  • 36. [Hepatorenal syndrome].
    Pŭrvanov P.
    Khirurgiia (Sofiia); 2002 Feb; 58(2):34-9. PubMed ID: 12515019
    [Abstract] [Full Text] [Related]

  • 37. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [The therapy of the hepatorenal syndrome in liver cirrhosis].
    Biecker E, Brensing KA, Perz J, Woitas R, Sauerbruch T.
    Dtsch Med Wochenschr; 1999 Sep 10; 124(36):1039-42. PubMed ID: 10506842
    [No Abstract] [Full Text] [Related]

  • 40. Hepatorenal syndrome: pathophysiology and management.
    Wadei HM, Mai ML, Ahsan N, Gonwa TA.
    Clin J Am Soc Nephrol; 2006 Sep 10; 1(5):1066-79. PubMed ID: 17699328
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.